In an open-label extension study, Lew et al. evaluated the long-term safety, efficacy, and tolerability of adjunctive selegi-line ODT 2.5 mg in patients who completed either of two large phase 3 double-blind studies. The study had been scheduled to end after 12 months, but it was amended to be open-ended.

A total of 254 patients were enrolled; 248 of these patients were selected from large phase 3 (efficacy analysis) studies, and the remaining six were from a previous open-label (safety analysis) comparison. Inclusion criteria from phase 3 studies consisted of a diagnosis of idiopathic PD, age older than 30 years, and deterioration of response at the end of the lev-odopa dosing interval with mild-to-moderate fluctuations. canadian pharmacy viagra

Patients in the open-label study had to be older than 18 years of age, in Hoehn and Yahr stage II or greater during off periods – and they had to have been treated with levodopa or a dopamine ag-oni st (or both) plus oral selegiline 10 mg/day for at least two months prior to enrollment in the study. Subjects were excluded:

• if they had any abnormal laboratory or oropharyngeal findings.
• if there were unresolved clinically significant adverse drug events.
• if they had used an MAO-B inhibitor other than generic selegiline ODT.
• if they had taken SSRIs, an opioid analgesic, or an antidepressant drug (other than one taken at a low dose or at night to improve sleep).

Among the 252 patients with available dosing data, 250 patients received selegiline ODT 2.5 mg/day and two patients were given a dose of 1.25 mg/day. One hundred seventy-one patients were randomly assigned to the continuing selegi-line ODT group, and 83 were assigned to the prior placebo group. Eighty-nine patients completed at least 40 weeks of the ongoing extension study; 165 discontinued the study prematurely before the end of the initial 40-week extension period. During the study, three patients received anticholinergic agents and six received dopamine agonists as part of their PD regimen. Other concomitant CNS agents consisted predominantly of analgesics.

Patients returned for clinic visits for efficacy and safety evaluations at four, six, nine, and 12 months after the initiation of treatment in the entry study and every six months thereafter if they successfully completed a screening visit. Safety was also assessed via telephone interviews – which took place midway between visits during the first year. Any changes in concomitant medications were evaluated along with modifications in dosages if necessary. buy antibiotics without prescription

The primary efficacy variable was the reduction in the percentage of average daily off time at each visit, compared with that at baseline. Patients and caregivers were instructed to record whether they had predominantly on or off periods, had on periods with dyskinesia, or were asleep, for each half-hour interval on two separate days during the week before the scheduled appointment. Secondary efficacy variables included average number of hours off per day reported on diary cards, changes in patient ratings of symptom improvement on the Patient’s Global Impression of Improvement (PGI-I) scale, and changes in investigator ratings of illness severity on the Clinical Global Impressions—Severity of Disease (CGI-S) scale.

Safety variables, which were reviewed at all clinic visits and by telephone, included adverse events and vital signs. A 12-lead electrocardiogram (ECG) was completed at the first visit, at week 40, and at the end of the study. Physical examinations were performed during the same time frame as well as annually. Blood chemistry and hematology parameters, oropharyngeal changes, and uri-nalyses were evaluated at all visits ex­cept at weeks four and 24.

The mean reductions from baseline in daily off time were 9.4% (1.6 hours) for patients who had previously been given selegiline ODT and 6% (1.2 hours) for patients who were switched from placebo. Overall, the average daily off time for the study population as a whole was 8.1%. No clinically significant differences were seen between men and women or between patients younger versus older than 65 years of age.

The reduction from baseline in average daily off hours until end of treatment for all patients who recorded offhours before their termination, regardless of how long they were in the study, was 1.4 hours (i.e., 1.6 hours for the continuing selegiline ODT group and 1.2 hours for the prior placebo group). discount drugs canda

The investigators concluded that the severity of disease was slightly worse at the end of treatment (mean CGI-S score, 3.7) than at baseline (mean CGI-S score, 3.3). Patients reported their condition as generally unchanged; thus, PGI-I scores did not differ between the two treatment groups.

No significant differences were detected in the incidence of adverse events in the continuing selegiline ODT group (161 of 171 patients, or 94.2%) and the prior placebo group (82 of 83 patients, or 98.8%). The adverse events that most often resulted in discontinuation of therapy were depression, hallucinations, and dyskinesia. The most common serious adverse events were accidental injury, chest pain, aggravation reaction, back pain, and pneumonia.

The laboratory values showed that high blood urea nitrogen (BUN) concentrations were considered to be clinically significant in only five of 78 patients and were not related to an underlying condition, according to the investigators. No other significant changes in blood chemistry profiles were noted.

At the end of treatment (n = 254), ECGs were normal in 80 patients (31.5%), abnormal but clinically insignificant in 165 patients (65%), and abnormal and clinically significant in six patients (2.4%). Clinically significant findings included premature supraventricular complexes, occasional premature supraventricular complexes, nonspecific ST-wave and T-wave abnormalities, unusual P-axis and atrial rhythms, sinus bradycardia and atrial premature depolarization, and evidence of left atrial enlargement. Oropharyngeal changes from baseline to end of therapy were minimal in both treatment groups. tadacip 20

The Lew study showed that continued, long-term therapy with once-daily sel-egiline ODT 2.5 mg in patients with significant motor fluctuations reduced daily off time by 1.6 hours over the course of more than three years.³ Patients in the placebo group benefited from initiation of therapy with selegiline ODT, but they achieved clinically insignificant reductions in off time.

In general, long-term selegiline ODT 2.5 mg/day was effective, safe, and well tolerated in PD patients experiencing off episodes during levodopa therapy.